{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:35:59Z","timestamp":1785332159487,"version":"3.55.0"},"reference-count":55,"publisher":"SAGE Publications","issue":"5_suppl","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:p>For many years, the mainstays of psoriasis therapy were conventional oral immunosuppressants (eg, cyclosporine and methotrexate) and retinoids. Recently, six biologic agents were approved for the treatment of psoriasis in Canada and the United States: alefacept, efalizumab, etanercept, infliximab, adalimumab, and ustekinumab. Biologic agents exert their therapeutic effect in psoriasis through inhibition of various pathways. Although these treatments are new to the management of psoriasis, many have been used in other disease states, such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease. Long-term safety data are available from the treatment of these diseases. Both conventional and biologic treatments are effective in the treatment of psoriasis, but they are associated with serious adverse events, ranging from organ toxicity to serious infections, birth defects, and malignancies. This article reviews the safety profiles of both classes of treatments.<\/jats:p>","DOI":"10.2310\/7750.2009.00023","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T15:01:24Z","timestamp":1426086084000},"page":"S67-S76","source":"Crossref","is-referenced-by-count":15,"title":["Safety of Conventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis"],"prefix":"10.1177","volume":"13","author":[{"given":"Robert","family":"Bissonnette","sequence":"first","affiliation":[{"name":"From Innovaderm Research, Montreal, QC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of British Columbia, Vancouver, BC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Dalhousie University, Halifax, NS"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2009,9,1]]},"reference":[{"key":"bibr1-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1111\/j.0366-077X.2004.05950.x"},{"key":"bibr2-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06563.x"},{"key":"bibr3-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"bibr4-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259327"},{"key":"bibr5-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(18)30284-5"},{"key":"bibr6-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2004.09.006"},{"key":"bibr7-7750.2009.00023","first-page":"95","volume":"13","author":"Mihatsch MJ","year":"1990","journal-title":"Br J Dermatol"},{"key":"bibr8-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70205-6"},{"key":"bibr9-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1990.tb02883.x"},{"key":"bibr10-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199206183262502"},{"key":"bibr11-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1993.tb15145.x"},{"key":"bibr12-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.387"},{"key":"bibr13-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80374-X"},{"key":"bibr14-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1997.tb02135.x"},{"key":"bibr15-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102010-00007"},{"key":"bibr16-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02977.x"},{"key":"bibr17-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12040.x"},{"key":"bibr18-7750.2009.00023","volume-title":"Trexall [package insert]","year":"2005"},{"key":"bibr19-7750.2009.00023","first-page":"757","volume":"7","author":"Ho V","year":"1995","journal-title":"Can J Dermatol"},{"key":"bibr20-7750.2009.00023","volume-title":"Soriatane [package insert]","year":"2008"},{"key":"bibr21-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2004.03.012"},{"key":"bibr22-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2006.00082.x"},{"key":"bibr23-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2006.00065"},{"key":"bibr24-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.6.719"},{"key":"bibr25-7750.2009.00023","volume-title":"Amevive [package insert]","year":"2006"},{"key":"bibr26-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030002"},{"key":"bibr27-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062382"},{"key":"bibr28-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1002\/art.23507"},{"key":"bibr29-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.2.197"},{"key":"bibr30-7750.2009.00023","volume-title":"Raptiva [package insert]","year":"2008"},{"key":"bibr31-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.021"},{"key":"bibr32-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08548.x"},{"key":"bibr33-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1159\/000095037"},{"key":"bibr34-7750.2009.00023","unstructured":"European Medicines Agency Press Office. European Medicines Agency recommends suspension of the marketing authorization of Raptiva (efalizumab) [news release]. Available at: http:\/\/www.emea.europa.eu\/pressoffice\/presshome.htm (accessed March 2, 2009)."},{"key":"bibr35-7750.2009.00023","unstructured":"US Food and Drug Administration. FDA Public Health Advisory. Updated safety information about Raptiva (efalizumab) [news release]. Available at: http:\/\/www.fda.gov\/cder\/drug\/advisory\/efalizumab.htm (accessed March 2, 2009)."},{"key":"bibr36-7750.2009.00023","first-page":"AB184","volume":"56","author":"Bala M","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"bibr37-7750.2009.00023","unstructured":"Burmester GR. Adalimumab safety profile in global clinical trials and reduction in standardized mortality ratio. Poster presented at American Academy of Dermatology Annual Conference; 2008 Feb 1\u20135; San Antonio, TX."},{"key":"bibr38-7750.2009.00023","unstructured":"Gordon K, Gottlieb A, Giannini EH. Clinical trial safety data of events of interest in patients receiving etanercept (ENBREL) across approved indications. Poster presented at American Academy of Dermatology Annual Conference; 2008 Feb 1\u20135; San Antonio, TX."},{"key":"bibr39-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1002\/art.21869"},{"key":"bibr40-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20169"},{"key":"bibr41-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1002\/art.21675"},{"key":"bibr42-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1002\/art.22864"},{"key":"bibr43-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1002\/art.23716"},{"key":"bibr44-7750.2009.00023","volume-title":"Remicade [package insert]","year":"2008"},{"key":"bibr45-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000077913.60364.D2"},{"key":"bibr46-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.2.223"},{"key":"bibr47-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087288"},{"key":"bibr48-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i6.974"},{"key":"bibr49-7750.2009.00023","unstructured":"Exarchou S, Voulgari P, Markatseli T, Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009 Jul 4:1\u20134. [Epub ahead of print: PMID: 19579151]"},{"key":"bibr50-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181441a68"},{"key":"bibr51-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-006-0561-8"},{"key":"bibr52-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.3.457"},{"key":"bibr53-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1126\/science.280.5368.1435"},{"key":"bibr54-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"bibr55-7750.2009.00023","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2310\/7750.2009.00023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2310\/7750.2009.00023","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2310\/7750.2009.00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:48:28Z","timestamp":1777391308000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2310\/7750.2009.00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":55,"journal-issue":{"issue":"5_suppl","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.2310\/7750.2009.00023"],"URL":"https:\/\/doi.org\/10.2310\/7750.2009.00023","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}